Current drug therapy for prostate cancer: an overview

Area of Science:

• Oncology
• Urology

Background:

• Prostate cancer is the most common cancer in US men and a leading cause of cancer death globally.
• Lifetime risk for a 50-year-old man is 42%, highlighting its growing impact on mortality, morbidity, and economy.

Purpose of the Study:

• To review current and emerging medical therapeutic options for prostate cancer.
• To discuss novel drugs targeting oncogenesis and metastasis.
• To consider prostate cancer chemoprevention and gene therapy.

Main Methods:

• Literature review of current medical therapeutic options.
• Discussion of traditional treatments: Luteinising hormone releasing analogues (LHRH), anti-androgens, and estrogen.
• Exploration of novel drugs, chemoprevention, and gene therapy.

Main Results:

• Traditional treatments like LHRH analogues, anti-androgens, and estrogens are established therapies.
• Novel drugs targeting molecular pathways in oncogenesis and metastasis show promise.
• Chemoprevention with 5alpha-reductase inhibitors and gene therapy are emerging strategies.

Conclusions:

• A comprehensive understanding of prostate cancer treatments is crucial for managing this growing health problem.
• The review provides an overview of established, novel, and future therapeutic avenues.
• Further research into targeted therapies, chemoprevention, and gene therapy is warranted.